CD19 Universal CAR-Gamma Delta T is under clinical development by Guangzhou Bio-gene Technology and currently in Phase II for Systemic Lupus Erythematosus. According to GlobalData, Phase II drugs for Systemic Lupus Erythematosus have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CD19 Universal CAR-Gamma Delta T’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CD19 Universal CAR-Gamma Delta T overview
The therapeutic candidate is under development for the treatment of refractory and moderately severe systemic lupus erythematosus. It comprises of T-cells genetically engineered to express chimeric antigen receptors (CAR) targeting cell expressing CD19 and is administered through intravenous route.
For a complete picture of CD19 Universal CAR-Gamma Delta T’s drug-specific PTSR and LoA scores, buy the report here.